However, according to a recent systematic review and global map of EGFR mutation incidence in NSCLC [39], the frequency of EGFR mutations among adenocarcinoma patients in the Asia-Pacific area ranges from 20% to 76%, and the mean frequency is 57% in Taiwan. This evidence concerns the gene EGFR and non-small cell lung carcinoma.